In PLOS this week: regulators of brown adipocyte differentiation, longevity and FOXO3 variants, and more.
The test is the fifth assay on the Solana platform to obtain clearance, and expands the firm's offerings in the women's health market.
The Public Health England lab plans to continue to use Oxford Nanopore's MinIon to help discover novel resistance mutations and elements that influence virulence.
Researchers use the CRISPR/Cas9 gene editing approach to limit herpesviruses replication.
The multiplex qPCR test can detect and discriminate herpes simplex virus 1 and 2 as well as varicella zoster virus, which can be mistaken for HSV in a proportion of cases.
The company issued the Class I recall in February because poor lamination between sample reaction wells led to inaccurate results, but has since resolved the issue.
The platform and the assay were cleared by the US Food and Drug Administration in October and were launched in the US shortly thereafter.
In PNAS this week: single-stranded cytosine deamination in E. coli, characterization of herpes simplex virus-1 microRNAs, and more.
The Austin, Texas-based molecular diagnostics firm logged $60.6 million in Q3 revenues as its system sales shot up 26 percent to $9.6 million.
The Australian firm provided an update on its in vitro diagnostics business, noting that it has also rebranded its core technologies and continues to license them.
Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.
University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.
The Wall Street Journal examines billing codes used by uBiome.
In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.